Prescott Group Capital Management L.L.C. Acquires Shares of 150,000 908 Devices Inc. (NASDAQ:MASS)

Prescott Group Capital Management L.L.C. acquired a new position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company's stock, valued at approximately $330,000. Prescott Group Capital Management L.L.C. owned about 0.43% of 908 Devices at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MASS. B. Riley Wealth Advisors Inc. bought a new stake in shares of 908 Devices in the 3rd quarter valued at about $45,000. Townsquare Capital LLC bought a new position in 908 Devices during the third quarter worth $50,000. Drive Wealth Management LLC bought a new position in shares of 908 Devices during the 3rd quarter worth approximately $50,000. Concurrent Investment Advisors LLC bought a new position in 908 Devices in the fourth quarter worth approximately $52,000. Finally, 49 Wealth Management LLC raised its stake in shares of 908 Devices by 16.2% in the third quarter. 49 Wealth Management LLC now owns 31,099 shares of the company's stock worth $108,000 after purchasing an additional 4,343 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

908 Devices Stock Performance

NASDAQ:MASS traded up $0.44 during trading hours on Tuesday, reaching $3.46. The company's stock had a trading volume of 1,404,952 shares, compared to its average volume of 3,812,128. The company has a market capitalization of $120.49 million, a P/E ratio of -1.95 and a beta of 0.99. 908 Devices Inc. has a 12 month low of $1.81 and a 12 month high of $7.56. The stock has a 50 day moving average price of $2.54 and a two-hundred day moving average price of $2.91.

Remove Ads

Wall Street Analysts Forecast Growth

MASS has been the topic of a number of recent research reports. Stifel Nicolaus dropped their price objective on 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Leerink Partners reissued a "market perform" rating and set a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stephens reissued an "overweight" rating and issued a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a report on Friday. Finally, Leerink Partnrs downgraded 908 Devices from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, 908 Devices presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.